Korean J Schizophr Res.  2020 Oct;23(2):51-57. 10.16946/kjsr.2020.23.2.51.

Pseudo-Resistant Schizophrenia: Non-Adherence to Treatment

• Kim H
• Lee SJ

• KMID: 2508352
• DOI: http://doi.org/10.16946/kjsr.2020.23.2.51

Abstract

Treatment-resistant schizophrenia (TRS) has been defined as the persistence of positive symptoms despite two or more trials of antipsychotic medication of adequate dose and duration. TRS is a serious clinical problem and occurs in approximately 30% of patients with schizophrenia. It is important that patients who do not adequately respond to antipsychotics be reevaluated to exclude or address causes other than non-responsiveness to medication, that is, the possibility of pseudo-resistance. In particular, non-adherence to oral antipsychotic treatment should be monitored to rule out pseudo-resistant cases of TRS. Moreover, patients with TRS who take their medication as required may have subtherapeutic antipsychotic plasma levels, secondary to pharmacokinetic factors. In this paper, we review the concept and exclusion of pseudo-resistance, especially owing to non-adherence or pharmacokinetic factors, and present methods to enhance drug adherence.

Keyword

Adherence; Pharmacokinetics; Pseudo-resistance; Schizophrenia; Treatment-resistance; 순응도; 약동학; 조현병; 치료 저항성; 치료 위저항성

Reference

1. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174:216–229.

2. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017; 62:772–777.

3. Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019; 80:18com12123.

4. Kinon BJ. The group of treatment resistant schizophrenias. heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry. 2018; 9:757.

5. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020; 6:1.

6. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014; 17:33–37.

7. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. Clin Psychopharmacol Neurosci. 2020; 18:386–394.

8. Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015; 25:1158–1166.

9. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007; 21:911–936.

10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209–1223.

11. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63:892–909.

12. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006; 8:232–241.

13. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67:1542–1550.

14. Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005; 133:129–133.

15. Bozzatello P, Bellino S, Rocca P. Predictive factors of treatment resistance in first episode of psychosis: a systematic review. Front Psychiatry. 2019; 10:67.

16. McCutcheon R, Beck K, D’Ambrosio E, Donocik J, Gobjila C, Jauhar S, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018; 137:39–46.

17. Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry. 2017; 174:421–426.

18. De Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004; 55:491–493.

19. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013; 27:1021–1048.

20. Flockhart D. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. 2007. [cited 2020 Oct 8]. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspx.

21. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003; 23:31–35.

22. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006; 11:126–135.

23. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. Sequencebased CYP2D6 genotyping in the Korean population. Ther Drug Monit. 2006; 28:382–387.

24. Hogan TP, Awad A, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983; 13:177–183.

25. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of Korean version of drug attitude inventory (KDAI-10). Korean J Psychopharmacol. 2005; 16:480–487.

26. Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr Res. 2000; 42:241–247.

27. Chang JG, Roh D, Kim CH. The reliability and validity of the Korean version of medication adherence rating scale. Korean J Psychopharmacol. 2015; 26:43–49.

28. Hemingway S. Medicines adherence-involving patients in decisions about prescribed medicines and supporting adherence: NICE clinical guideline 76. Ment Health Nurs. 2009; 29:10.

29. Wilder CM, Elbogen EB, Moser LL, Swanson JW, Swartz MS. Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatr Serv. 2010; 61:380–385.

30. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv. 2008; 59:1207–1210.

31. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised 1976 (Abnormal Involuntary Movement Scale [AIMS]). Rockville Maryland: National Institute of Mental Health;1976. p. 534–537.

32. Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008; 22:238–243.

33. Day J, Wood G, Dewey M, Bentall R. Liverpool university neuroleptic side effect rating scale. Br J Psychiatry. 1995; 166:650–653.

34. Jung HY, Kim JH, Ahn YM, Kim SC, Hwang SS, Kim YS. Liverpool university neuroleptic side-effect rating scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Hum Psychopharmacol. 2005; 20:41–45.

35. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011.

36. Hasan AA, Callaghan P, Lymn JS. Evaluation of the impact of a psycho-educational intervention for people diagnosed with schizophrenia and their primary caregivers in Jordan: a randomized controlled trial. BMC Psychiatry. 2015; 15:72.

37. Alhadidi MM, Abdullah KL, Yoong TL, Hadid LA, Danaee M. A systematic review of randomized controlled trials of psychoeducation interventions for patients diagnosed with schizophrenia. Int J Soc Psychiatry. 2020; 66:542–552.

38. Boczkowski JA, Zeichner A, DeSanto N. Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report. J Consult Clin Psychol. 1985; 53:666.

39. Razali SM, Hasanah CI, Khan A, Subramaniam M. Psychosocial interventions for schizophrenia. J Ment Health. 2000; 9:283–289.

40. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry. 2006; 163:365–373.

41. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis. 1999; 187:53–55.

42. Eckman TA, Wirshing WC, Marder SR, Liberman RP, JohnstonCronk K, Zimmermann K, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry. 1992; 149:1549–1555.

43. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998; 172:413–419.

44. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry. 2000; 157:1317–1328.

45. Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, et al. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008; 102:312–319.

46. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015; 72:822–829.

47. Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019; 80:IN18031AH1C.

48. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry. 2017; 74:686–693.

49. Gibson TB, Jing Y, Kim E, Bagalman E, Wang S, Whitehead R, et al. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care. 2010; 19:40–47.

50. Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, et al. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial. BMJ. 2013; 347:f5847.

51. Burton A, Marougka S, Priebe S. Do financial incentives increase treatment adherence in people with severe mental illness? a systematic review. Epidemiol Psichiatr Soc. 2010; 19:233–242.

52. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012; 5:320–331.

53. Heo JU, Kim DW, Oh ST, Choi WJ, Park J. Clinical characteristics, drug adherence to antipsychotics and medical use trends in patients first diagnosed with psychotic disorder: a preliminary study. Kor J Schizophr Res. 2019; 22:35–50.